Local Delivery of Silk Fibroin and Chlorhexidine

A Comparative Evaluation of Subgingivally Delivered Chlorhexidine, Silk Fibroin and Combination of Fibroin and Chlorhexidine as Local Drug Delivery in Periodontitis - A Randomized Control Trial

The current study is a prospective randomised split mouth study to evaluate the effect of Silk fibroin as drug delivery system while simultaneously assessing the efficacy of silk fibroin in comparison to chlorhexidine.

Fifteen healthy individuals satisfying the inclusion and exclusion criteria were recruited for the study. A detailed, thorough medical and dental history was obtained and each patient was subjected to comprehensive clinical and radiological examination. All patients were informed about the nature of the study, procedure involved, potential benefits and risks associated with procedure and written informed consent were obtained from all patients.All the patients underwent scaling and root planing. Following randomization, the site will be assigned to one of the three study groups. Group I (SRP+ Silk Fibroin) Group II (SRP+ Chlorhexidine) Group III (SRP+ Combination of Fibroin and Chlorhexidine) Periodotal pack was placed and patient was recalled after 21days, 1 month and 3 month for the follow up.

silk fibroin extracted from bombyx mori silk worm is processed in laboratory to form silk fibroin films

measured using a UNC-15 probe (university of North Carolina-15 periodontal probe- Hu-Friedy, Chicago, IL, USA

measured by placing the acrylic stent on the selected teeth using UNC-15 probe (university of North Carolina-15 periodontal probe- Hu-Friedy, Chicago, IL, USA)

Inclusion Criteria: Patient with age between 30-50 years. Patients with stage I/ II with Grade A/ B periodontitis according to 2017 World workshop classification of periodontal disease will be considered. Patients with localized periodontal pockets. Patients willing to participate in the study. Exclusion Criteria: Patients with known systemic diseases. Non complaint patients. Patients who received any surgical or nonsurgical therapy 6 months before the start of the study. Pregnant or lactating females. Use of systemic antibiotics in the past 6 months.